research use only

TYRA-300 FGFR inhibitor

Name: TYRA-300
Brand: Selleck Chemicals
SKU: E4727
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E4727

TYRA-300 , a 3-pyridylindazole analog, is a reversible and selective inhibitor of FGFR3 with an IC50 of 11 nM in Ba/F3 cells. It also exhibit potent activity in human bladder cancer cell lines harboring FGFR3 activating fusions or mutations.

Chemical Structure

Molecular Weight: 559.47

Jump to

Quality Control

Batch: E472701 DMSO]100 mg/mL]false]Ethanol]3 mg/mL]false]Water]Insoluble]false Purity: 99.07%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

99.07

Related Targets	EGFR VEGFR PDGFR c-Met Src MEK CSF-1R FLT3 HER2 c-Kit
Other FGFR Inhibitors	PD173074 AZD4547 (Fexagratinib) BLU9931 Futibatinib (TAS-120) LY2874455 H3B-6527 PD-166866 Fisogatinib (BLU-554) Zoligratinib (Debio-1347) SSR128129E

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (178.74 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 3 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5mg/ml (8.94mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.5mg/ml (0.89mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	559.47	Formula	C₂₅H₂₄Cl₂N₆O₃S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	2800223-30-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

References	[1] https://pubmed.ncbi.nlm.nih.gov/39258897/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-21)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07265947	RECRUITING	Low Grade Upper Tract Urothelial Carcinoma	Tyra Biosciences, Inc	2025-12-22	PHASE2
NCT06842355	RECRUITING	Achondroplasia	Tyra Biosciences, Inc	2025-03-04	PHASE2
NCT06995677	RECRUITING	Low-grade NMIBC; FGFR Gene Amplification; FGFR Gene Alterations; FGFR3 Gene Alteration; FGFR3 Gene Mutation; FGFR3 Gene Fusions	Tyra Biosciences, Inc	2025-06-27	PHASE2
NCT05544552	ACTIVE_NOT_RECRUITING	Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Urothelial Carcinoma; Solid Tumor, Adult; Bladder Cancer; Non-muscle-invasive Bladder Cancer; FGFR3 Gene Mutation; FGFR3 Gene Alteration; Advanced Solid Tumor; Advanced Urothelial Carcinoma; Urinary Tract Cancer; Urinary Tract Tumor; Urinary Tract Carcinoma	Tyra Biosciences, Inc	2022-11-22	PHASE1; PHASE2
NCT06006702	ACTIVE_NOT_RECRUITING	Healthy	Tyra Biosciences, Inc	2023-10-16	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):